key: cord-0777247-fl15okfa
authors: Lednicky, John A
title: A Practical and Economic Approach for Assessing Potential Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Transmission Risk in Coronavirus Disease 2019 (COVID-19) Patients
date: 2020-12-01
journal: Clin Infect Dis
DOI: 10.1093/cid/ciaa1789
sha: b77ebc0a89d5882dd669872fecf9bdb61fcb0d43
doc_id: 777247
cord_uid: fl15okfa

nan

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), has proven to be a formidable foe. Almost a year after the start of the COVID-19 pandemic, record numbers of cases are reported almost daily in the United States and elsewhere in the world. For example, according to the Johns Hopkins School of Medicine Coronavirus Resource Center [1] , 184 514 new COVID-19 cases were recorded on 13 November in the United States and 153 496 cases the previous day. These numbers set single-day records for the United States. What accounts for the large number of new COVID-19 cases every day that are reported worldwide? Many complex factors contribute to the current state of the pandemic. These include insufficient funding of public health institutions, inattention to or lapses in proper infection control practices, adaptive mutation(s) in SARS-CoV-2 that facilitate its life cycle in humans, and inadequate understanding of how the virus is transmitted person to person, especially with regard to aerosols.

To control the pandemic, we must gain a better understanding of the natural biology of SARS-CoV-2. This will lead to more accurate risk-of-infection analyses, and that knowledge will better inform approaches used to curtail exposure to SARS-CoV-2 in work, residential, and other settings. Since the start of the pandemic, countless reports have documented the presence for SARS-CoV-2 genomic RNA (vRNA) on environmental surfaces and in the air of the rooms of hospitalized COVID-19 patients. Others have reported the presence of SARS-CoV-2 vRNA in vehicles, living spaces, in sewage samples, and so forth. Because few of the studies attempted virus isolation, much of the knowledge accumulated so far has been applied incorrectly for infection control. Indeed, previous efforts emphasized hand washing and so forth. But proper risk-of-infection analysis requires knowledge whether the SARS-CoV-2 vRNA stems from a viable (infectious) virion (defined as a completely formed and infectious virus particle). Clearly, noninfectious SARS-Cov-2 virions cannot cause COVID-19, and reverse transcription polymerase chain reaction (RT-PCR) tests do not discriminate between infectious and noninfectious virions. Moreover, nasopharyngeal swab and other similar specimens taken from COVID-19 patients contain a mixture of virions and infected cells and cell debris that contain SARS-CoV-2 vRNA not packaged in virions and SARS-CoV-2 messenger RNAs (mRNAs) that are also detected by commonly used RT-PCR tests. Importantly, a growing body of evidence indicates that after about 8 days of onset of symptoms, that for most COVID-19 patients, infectious virus is not present in respiratory tract specimens despite high amounts of SARS-CoV-2 RNA that is measurable by RT-PCR. These observations have confounded epidemiology assessments based on detection of SARS-CoV-2 RNA: when is the greatest risk posed by a COVID-19 patient?

Unfortunately, relatively few clinical microbiology laboratories have BSL3 facilities, which are required for the isolation of SARS-CoV-2 in cell cultures. This problem is amplified in resourcestrapped public-health laboratories and is a world-wide problem. Apart from BSL3 facility requirements, the isolation of SARS-CoV-2 in cell cultures can be time consuming and is costly. Thus, from a clinical/diagnostic perspective, virus isolation is not practical for many reasons and cannot be used for rapid reporting of test results. There is thus a major and real need for a quick and economic approach for assessing risk of exposure to infectious SARS-CoV-2 produced by COVID-19 patients. To that end, a timely and important contribution has been made by Dr A. Pekosz and colleagues as outlined in their article titled "Antigen-based testing but not real-time PCR correlated with SARS-CoV-2 virus culture" in this issue of Clinical Infectious Diseases [2] .

The authors have crafted a welldesigned and compelling study that generates much needed new information that should be considered for COVID-19 infection-control guidelines [2] . The major thrust of this study was to see whether detection of SARS-CoV-2 antigen during the acute phase of COVID-19 (the time when infectious virions are detected) could be attained using a new commercial product (BD Veritor System for Rapid Detection of SARS-CoV-2) and whether the results matched virus isolation using an optimal SARS-CoV-2 isolation procedure. For this study, archived (previously tested and chosen for the study) residual respiratory swab specimens from COVID-19 patients in 21 geographically diverse study sites were analyzed in 3 manners: (a) RT-PCR, (b) antigen test, and (c) virus culture. The most important finding of this work is that, indeed, the quick antigen detection system provides results that correlate with virus isolation, that is, that antigen detection correlates with presence of infectious virus. This raises the question of what is the nature of the vRNA detected at later times during the course of COVID-19? Does it stem from infected cells that are being cleared by the immune system?

The execution of this study has notable technical strengths. Foremost is the overall study design, which merges classic public health approaches with gold-standard virology work. Moreover, aspects of the work were performed at different sites, and that reduces bias because independent analysts performed the tests, and the overall results indicate agreement between the test sites. Finally, the data are analyzed with rigor.

The results of this work surface important considerations regarding the risk of transmission period posed by COVID-19 patients. A very useful aspect are the technical approaches used by the authors for clinical diagnostics, including the following: (a) the study was performed using an antigen detection system that has not been extensively evaluated by clinical and research laboratories and thus provides useful information regarding a practical application for this product, and (b) the RT-PCR system they used (from the Quidel Corporation) is also somewhat less familiar to many diagnostic laboratories, and the authors provide validation for its use. Taken together, the authors describe a potentially practical and cost-efficient as well as rapid approach to risk assessment for COVID-19 patients. Time will show whether this will result in cost reductions in the manner by which hospitalized patients are managed. For instance, can we safely move patients outside of isolation rooms once they are past the 8-day after onset-of-symptoms time point? Can less expensive respirators be used in dealing with such patients?

In summary, this is a well-written and presented body of work, and the information therein elevates this to a must-read article that also provides an outline for a practical and economic approach for assessing potential SARS-CoV-2 transmission risk in COVID-19 patients.

Antigen-based testing but not real-time PCR correlated with SARS-CoV-2 virus culture

Potential conflicts of interest. The author: No reported conflicts of interest. The author has submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.